Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial

Toby M. Maher(Royal Brompton Hospital), Tamera J. Corte(Royal Prince Alfred Hospital), Aryeh Fischer(Bristol-Myers Squibb (United States)), Michael Kreuter(Heidelberg University), David J. Lederer(Columbia University Irving Medical Center), María Molina‐Molina(Centro de Investigación Biomédica en Red de Enfermedades Respiratorias), Judit Axmann(Roche (Switzerland)), Klaus-Uwe Kirchgaessler(Roche (Switzerland)), Katerina Samara(Roche (Greece)), Frank Gilberg(Roche (Switzerland)), Vincent Cottin(Hôpital Louis Pradel)
The Lancet Respiratory Medicine
September 29, 2019
Cited by 625

Abstract


Related Papers

No related papers found

Powered by citation graph analysis